Search Results
Search for other papers by Tullio Florio in
Google Scholar
PubMed
Search for other papers by Federica Barbieri in
Google Scholar
PubMed
Search for other papers by Renato Spaziante in
Google Scholar
PubMed
Search for other papers by Gianluigi Zona in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by Peter M van Koetsveld in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
Search for other papers by Michael D Culler in
Google Scholar
PubMed
Search for other papers by Jesse Dong in
Google Scholar
PubMed
Search for other papers by John E Taylor in
Google Scholar
PubMed
Search for other papers by Jacques-Pierre Moreau in
Google Scholar
PubMed
Search for other papers by Alexandru Saveanu in
Google Scholar
PubMed
Search for other papers by Ginette Gunz in
Google Scholar
PubMed
Search for other papers by Henry Dufour in
Google Scholar
PubMed
Search for other papers by Philippe Jaquet in
Google Scholar
PubMed
to be more effective than each single agonist in the growth hormone (GH)-secreting adenomas, partially responding to octreotide ( Jaquet et al . 2005 ). Thus, we investigated the efficacy of one of these dopamine–somatostatin chimeric compounds
Search for other papers by P J Jenkins in
Google Scholar
PubMed
Search for other papers by S Khalaf in
Google Scholar
PubMed
Search for other papers by W Ogunkolade in
Google Scholar
PubMed
Search for other papers by K McCarthy in
Google Scholar
PubMed
Search for other papers by T David in
Google Scholar
PubMed
Search for other papers by R E Hands in
Google Scholar
PubMed
Search for other papers by D Davies in
Google Scholar
PubMed
Search for other papers by S A Bustin in
Google Scholar
PubMed
. While serum levels of IGF-I, which are regulated by growth hormone (GH), are generally considered to be a positive risk factor for the development of colorectal cancer, the role of IGFBP-3 appears less clear. Some studies suggest it exerts a protective
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Sayka Barry in
Google Scholar
PubMed
Search for other papers by Eivind Carlsen in
Google Scholar
PubMed
Search for other papers by David Collier in
Google Scholar
PubMed
Search for other papers by Amy Ronaldson in
Google Scholar
PubMed
Search for other papers by Sherine Awad in
Google Scholar
PubMed
Search for other papers by Neil Dorward in
Google Scholar
PubMed
Search for other papers by Joan Grieve in
Google Scholar
PubMed
Search for other papers by Nigel Mendoza in
Google Scholar
PubMed
Search for other papers by Samiul Muquit in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Search for other papers by Frances Balkwill in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
.078006 ) Castro CP Giacomini D Nagashima AC Onofri C Graciarena M Kobayashi K Paez-Pereda M Renner U Stalla GK Arzt E 2003 Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of
Department of Endocrinology, King’s College Hospital NHS Foundation Trust, London, UK
Search for other papers by Paraskevi Xekouki in
Google Scholar
PubMed
Department of Endocrinology and Diabetes, King’s College London, London, UK
Search for other papers by Emily J Lodge in
Google Scholar
PubMed
Search for other papers by Jakob Matschke in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Alice Santambrogio in
Google Scholar
PubMed
Histopathology Department, Great Ormond Street Hospital NHS Trust, London, UK
Search for other papers by John R Apps in
Google Scholar
PubMed
Search for other papers by Ariane Sharif in
Google Scholar
PubMed
Histopathology Department, Great Ormond Street Hospital NHS Trust, London, UK
Search for other papers by Thomas S Jacques in
Google Scholar
PubMed
Search for other papers by Simon Aylwin in
Google Scholar
PubMed
Search for other papers by Vincent Prevot in
Google Scholar
PubMed
Search for other papers by Ran Li in
Google Scholar
PubMed
Search for other papers by Jörg Flitsch in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Cynthia L Andoniadou in
Google Scholar
PubMed
signalling cascade in pituitary gland pathophysiology. Mice deficient for Lats1 ( Lats1 − / − ) present with hyperplasia of the anterior pituitary lobe, but reduced secretion of hormones such as LH, PRL and GH ( St John et al. 1999 ). We
Laboratory of Molecular Oncology, School of Molecular Medicine, Institut Gustave Roussy, Emory University School of Medicine, Department of Oncology, Military Institute of Medicine, Szaserow 128, 04‐141 Warsaw, Poland
Search for other papers by W Solarek in
Google Scholar
PubMed
Search for other papers by A M Czarnecka in
Google Scholar
PubMed
Search for other papers by B Escudier in
Google Scholar
PubMed
Laboratory of Molecular Oncology, School of Molecular Medicine, Institut Gustave Roussy, Emory University School of Medicine, Department of Oncology, Military Institute of Medicine, Szaserow 128, 04‐141 Warsaw, Poland
Search for other papers by Z F Bielecka in
Google Scholar
PubMed
Search for other papers by F Lian in
Google Scholar
PubMed
Search for other papers by C Szczylik in
Google Scholar
PubMed
-releasing hormone antagonist (GH-RH) and somatostatin analog on the proliferation of the human RCC cell line Caki-1 (isolated from skin metastasis) in vitro and in vivo . They showed that both GH-RH antagonist and somatostatin analog inhibit the growth of the
Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA
Search for other papers by Elena Sabini in
Google Scholar
PubMed
Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA
Search for other papers by Amna Khan in
Google Scholar
PubMed
Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA
Search for other papers by Patrizio Caturegli in
Google Scholar
PubMed
quantities that cause a clinical syndrome, just as Cushing disease arises from the hypersecretion of adrenocorticotropic hormone (ACTH) or acromegaly from the hypersecretion of growth hormone (GH) ( Asa et al. 2022 ). Other adenomas do not produce increased
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Ioannis I Androulakis in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
cell of origin ( Keffer 1996 ). The term ‘paraneoplastic syndromes’ (PNSs) is used to denote an array of symptom complexes that are manifested systemically as the result of the production of hormones, growth factors, cytokines and/or other substances by
Unit of Neuropathology, Unit of Internal Medicine and Endocrinology, Unit of Neurosurgery, Department of Experimental Medicine, Neuromed Institute, Unit of Pediatric Endocrinology, University of Paris‐Sud, Department of Pediatric Neurosurgery, Department of Endocrinology, INSERM U984 Laboratory of Glial Plasticity, Centre Hospitalier Sainte Anne, University of Paris Descartes, 1 Rue Cabanis, 75014 Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Maria Stefania Lagonigro in
Google Scholar
PubMed
Search for other papers by Flavia Magri in
Google Scholar
PubMed
Search for other papers by Maria Koziak in
Google Scholar
PubMed
Unit of Neuropathology, Unit of Internal Medicine and Endocrinology, Unit of Neurosurgery, Department of Experimental Medicine, Neuromed Institute, Unit of Pediatric Endocrinology, University of Paris‐Sud, Department of Pediatric Neurosurgery, Department of Endocrinology, INSERM U984 Laboratory of Glial Plasticity, Centre Hospitalier Sainte Anne, University of Paris Descartes, 1 Rue Cabanis, 75014 Paris, France
Search for other papers by Marie-Lise Jaffrain-Rea in
Google Scholar
PubMed
Search for other papers by Raja Brauner in
Google Scholar
PubMed
Search for other papers by Jerome Bouligand in
Google Scholar
PubMed
Search for other papers by Marie Pierre Junier in
Google Scholar
PubMed
Search for other papers by Federico Di Rocco in
Google Scholar
PubMed
Search for other papers by Christian Sainte-Rose in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by François Xavier Roux in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Luca Chiovato in
Google Scholar
PubMed
supported by the lack of growth disorders and other clinical symptoms or signs attributable to somatotrope hypersecretion. Owing to this lack of suggestive symptoms or signs in advance of emergency presentation, the standard hormonal workup (including
Search for other papers by Cindy M Staka in
Google Scholar
PubMed
Search for other papers by Robert I Nicholson in
Google Scholar
PubMed
Search for other papers by Julia M W Gee in
Google Scholar
PubMed
exquisitely low residual steroid hormone levels now appear sufficient to support tumour cell growth. Indeed, Santen et al. (2004) have shown oestradiol concentrations as low as 10 −14 M maximally stimulate growth of their ER+ long-term oestrogen deprived
Search for other papers by Meng-Lei Zhu in
Google Scholar
PubMed
Search for other papers by Natasha Kyprianou in
Google Scholar
PubMed
transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells . Endocrinology 142 2419 – 2426 . Bruckheimer EM Kyprianou N 2002 BCL-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and